SIFI SpA   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Lavina Italy (1935)
Status: No NME R&D (1935)

Organization Overview

First Clinical Trial
2015
NCT02506257
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

SIFI SpA

Active Ingredients

Drugs in Phase 3 Trials (4)

neomycin (1 trial)

Polyhexanide (1 trial)

propamidine isetionate (Brolene) (1 trial)

urea (1 trial)

Drugs in Phase 2 Trials (1)

progesterone (progestasert) (1 trial)

Drugs in Phase 1 Trials (1)

polihexanide (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acanthamoeba Keratitis (Phase 3)

Cataract (Phase 3)

Keratitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 6